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ABSTRACT
Anti-VEGF therapy with Bevacizumab is approved for glioblastoma treatment, 
however, it is known that tumors acquired resistance and eventually became even 
more aggressive and infiltrative after treatment. In the present study we aimed 
to unravel the potential cellular mechanisms of resistance to Bevacizumab in 
glioblastoma in vitro models.
Using a panel of glioblastoma cell lines we found that Bevacizumab is able to 
block the secreted VEGF by the tumor cells and be internalized to the cytoplasm, 
inducing cytotoxicity in vitro. We further found that Bevacizumab increases the 
expression of hypoxic (HIF-1α and CAIX) and glycolytic markers (GLUT1 and MCT1), 
leading to higher glucose uptake and lactate production. Furthermore, we showed that 
part of the consumed glucose by the tumor cells can be stored as glycogen, hampering 
cell dead following Bevacizumab treatment. Importantly, we found that this change on 
the glycolytic metabolism occurs independently of hypoxia and before mitochondrial 
impairment or autophagy induction. Finally, the combination of Bevacizumab with 
glucose uptake inhibitors decreased in vivo tumor growth and angiogenesis and shift 
the expression of glycolytic proteins.
In conclusion, we reported that Bevacizumab is able to increase the glucose 
metabolism on cancer cells by abrogating autocrine VEGF in vitro. Define the effects 
of anti-angiogenic drugs at the cellular level can allow us to discover ways to revert 
acquired resistance to this therapeutic approaches in the future.
INTRODUCTION
Gliomas are the most common group of brain tumors, 
representing approximately 70%. Glioblastoma (GBM) is 
the most common and aggressive glioma in adults [1–4]. 
Standard treatment consists of surgical resection followed by 
radiotherapy plus concomitant and adjuvant temozolomide 
chemotherapy. However, this regimen offers modest benefits 
with a median overall survival of only 16 months [4–8]. 
Therefore, a better understanding of GBM biology and more 
effective therapeutic options are warranted. In the recent 
years, new strategies to improve cancer treatment, such as the 
usage of molecular targeted therapies, that selectively target 
altered proteins in cancer cells, have been developed [9].
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GBM is one of the most vascularized human tumors, 
with disorganized tumor vessels, highly permeable and 
presenting abnormal endothelial walls [10, 11]. Therefore, 
they have a high angiogenic capacity producing a variety 
of pro-angiogenic factors, including VEGF (Vascular 
endothelial growth factor) [12, 13]. In the last years, 
VEGF-A became an attractive strategy for targeting 
angiogenesis in cancer patients [1], since is the most 
common isoform present in tumor tissues, being also 
associated with patient’s worse prognosis [13].
Bevacizumab (Avastin® - Beva), a humanized 
anti-VEGF monoclonal antibody, was the first approved 
anti-VEGF therapy by the United States Food and Drug 
Administration (FDA) in 2004. It was first approved to 
metastatic colorectal cancer and non-small cell lung cancer 
treatment in combination with other chemotherapeutic 
agents [14, 15]. In GBM, Beva was approved as a second 
line treatment option in combination with chemotherapy 
[16, 17]. Currently, is in phase III clinical trials as first 
line usage in GBM treatment. In the phase II trials, alone 
or in combination with standard therapy, it was observed 
that Beva clearly increases the radiographic response on 
magnetic resonance imaging, resulting in an increased 
progression free survival of 6 months. Conversely, the 
impact on overall survival was unclear [18–23]. Thus, the 
clinical benefits of anti-VEGF therapy in most patients are 
transient and followed by a restoration of angiogenesis, 
tumor progression and invasion [24].
Recently, several reports have demonstrated that the 
metabolic rewiring of cancer cells can also be responsible 
for resistance to oncogene-targeted therapies (reviewed in 
[25]). Accumulating evidences have also associated the 
reprogramming of metabolism in the acquired resistance 
to Beva treatment [26, 27]. The in vivo studies have 
shown that the reduced perfusion, associated with Beva 
treatment, causes a decrease on nutrients and oxygen 
supply, leading to the development of hypoxia in the 
tumor microenvironment [24, 26–28], and consequently 
to the remodeling of glycolytic metabolism [26–37].
The cellular mechanisms through which metabolic 
alterations occur on tumor cells upon VEGF-targeted 
therapies are still unknown. Accordingly, the major aim of 
this work was to study whether these metabolic alterations 
can occur already at the cellular level and independently 
of tumor microenvironment or hypoxia, trying to propose 
new tools, such as in vitro models, to study ways overcome 
Beva associated resistance.
RESULTS
Bevacizumab is internalized by GBM cells and 
impairs in vitro cell viability
Beva is a monoclonal antibody designed to target 
specifically the ligand VEGF-A. This ligand, in the 
tumor microenvironment, is supposedly secreted to the 
extracellular region to stimulate VEGF receptors that are 
present in endothelial cells. Thus, in the present work we 
initially aimed to determine whether GBM tumor cells 
secret VEGF or whether they can be expressing VEGF 
intracellularly, and how Beva can enter the cell and 
recognize it in vitro. For that we co-stained two GBM 
cell lines, and one brain endothelial cell line (HBMEC) 
as control, with VEGF and Beva as primary antibodies. 
We found that all cell lines express VEGF in the cytosol 
and that Beva recognizes an intracellular protein that co-
localizes exactly with VEGF, as expected (Figure 1A).
In order to determine the cytotoxic effect of Beva, 
a panel of GBM cell lines were treated with increasing 
concentrations of Beva during 72 hours and cellular 
viability was assessed by MTS assay. Excepting A172 
cells, all the other cell lines reached an IC50 value of up to 
1mg/ml (Figure 1B).
To further confirm its functionality in vitro, the cells 
were treated by 24 hours with a non-cytotoxic dose of 
Beva, as showed by the absence of PARP cleavage (Figure 
1C). We found that the intracellular VEGF was decreased 
after Beva treatment, as shown by a diminishment of the 
protein levels by western blot (Figure 1C). In addition, 
by ELISA assay we showed that GBM cells secret VEGF 
proportionally to the number of existing cells, being that 
ligand completely abolished from the culture medium after 
Beva treatment (Figure 1D).
Next, we wondered whether Beva could be 
internalized by the tumor cells. For that we treated all cell 
lines with Beva and used an anti-human IgG antibody to 
follow its location. As it can be observed on Figure 1E, we 
found that Beva is internalized, being located mainly at the 
cytoplasm, presenting in some cell lines a dot-like staining 
(Figure 1E). Moreover, it can be observed in some cell 
lines (e.g. GAMG, SW1783 and A172) an accumulation of 
Beva at the extracellular region (attached to the coverslip).
Overall, these findings re-enforces our hypothesis 
that Beva can be used in vitro, being functional and having 
biological and cytotoxic activity. Importantly, this in vitro 
effect of Beva was not specific for GBM, occurring also 
in lung and colorectal cell lines (Supplementary Figure 1).
Bevacizumab treatment alters the glycolytic 
metabolism of glioblastoma cells
To determine whether Beva promotes the glycolytic 
metabolism independently on oxygen depletion, and 
consequently hypoxia, we used GBM in vitro models by 
selecting two cell lines with different metabolic behaviors; 
U251 as one of the most glycolytic GBM cell line, and 
SW1088, as a more oxidative cell line, as previously 
described by our group [38, 39].
Beva treatment increased significantly the glucose 
consumption in the two cell lines (Figure 2A), an increase 
that was accomplished by an increased expression of 
hypoxic markers, such as HIF-1α (hypoxia-inducible factor 
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Figure 1: In vitro effect of Bevacizumab in GBM cell lines. (A) Immunofluorescence for VEGFA using a specific anti-VEGF 
antibody and Beva as primary antibodies. (B) Cell viability of GBM cell lines exposed to increasing concentrations of Beva was assessed by 
MTS assay at 72 hours of treatment; results are from three independent assays, each one in triplicates. (C) Western Blot analysis for VEGF 
and the apoptotic marker (PARP cleavage). The cells were treated with 2 mg/ml of Beva during 24 hours. (D) ELISA assay for human 
VEGF. The cells were seeded in different numbers and the supernatant of the cells was collected after 24 hours of Beva treatment (2 mg/ml) 
for VEGF quantification. (E) Beva internalization was evaluated in GBM cell lines treated during 24 hours with Beva (2 mg/ml) by using 
an anti-human IgG antibody. On the images from (A) and (E) the cell nucleus were counterstained with DAPI and the pictures were taken 
at 400x in an Olympus fluorescence microscope.
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1-alpha) and CAIX (Carbonic anhydrase 9) (Figure 2B 
and 2C), as well as an increase in the glycolytic markers 
(Figure 2B), being mainly verified a preferential location 
of GLUT1 (glucose transporter 1) at the plasma membrane 
(Figure 2C). No alterations on the expression of other 
metabolic markers, such as hexokinase II (HKII) and lactate 
dehydrogenase (LDHA), were observed both by western 
blot or immunofluorescence (Figure 2B and 2C).
Furthermore, since it was observed an increase on 
glucose uptake and glycolytic markers expression upon 
Beva treatment, we intended to study whether this drug 
can promote Warburg effect by increasing the levels of 
lactate production (Figure 3). Thus, we observed that 
only 2mg/ml Beva increased the lactate production on 
U251 cells, whereas both concentrations of Beva (1mg/
ml and 2mg/ml) were able to significantly increase 
the lactate production on SW1088 cells (Figure 3A). 
Additionally, an increase on the lactate transporter 
MCT1 (monocarboxylate transporters 1) at the plasma 
membrane was observed in both cell lines (Figure 3B and 
3C). Neither the transporter MCT4 (monocarboxylate 
transporters 4) nor its chaperone CD147 were altered upon 
Beva treatment in both cell lines (Figure 3B and 3C).
The effect of Beva on glucose metabolism was 
also confirmed in colon and lung cancer cell lines 
(Supplementary Figure 2).
Bevacizumab treatment promotes glycogen 
accumulation as a potential survival mechanism
To understand whether the changes on the glycolytic 
metabolism driven by Beva can be due mitochondria 
impairment, we assessed mitochondrial activity and 
production of reactive oxygen species (ROS). We observed 
that Beva did not induce significant changes in ROS 
production (Figure 4A), nor in the ratio of mitochondrial 
polarization/mitochondrial mass in U251 cell line, but 
increases mitochondrial activity in SW1088 cells after 48 
hours of Beva treatment at 2 mg/ml (Figure 4B).
It is well described that cells undergoing hypoxia 
have the ability to store the consumed glucose into 
glycogen as a survival mechanism [40]. It is also known 
Figure 2: Effect of Bevacizumab treatment on glucose metabolism of GBM cells. (A) Beva increased the glucose consumption 
of U251 and SW1088 cells after 48 hours of treatment; results are representative of three independent experiments, each one in triplicates; 
*p<0.05, ****p≤0.0001 Beva vs control.  Western blot (B) and immunofluorescence (C) of hypoxia markers and glycolytic markers in 
U251 and SW1088 cells treated with 2mg/ml Beva during 48 hours. Increased HIF-1α, CAIX and GLUT1 expression was observed after 
treatment. The cell nucleus were counterstained with DAPI and the pictures were taken at 400x in an Olympus fluorescence microscope.
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that hypoxia-mediated autophagy promotes tumor cell 
survival [41]. Since Beva does not show a significant 
impact on mitochondrial impairment, and we have 
observed that the glucose consumed was not all converted 
into lactate (comparing graphs from Figure 2 and 3), 
we screened for alterations on glycogen synthesis and 
autophagy induction after Beva treatment. By PAS staining 
we observed an increase on glycogen accumulation on 
cells treated during 48 hours with Beva, an effect that 
seems to be dose dependent (Figure 4C). Accordingly, 
Figure 3: Modulation of lactate production and transport in Bevacizumab treated GBM cells. (A) The lactate export is 
increased in U251 and SW1088 cells treated with 2mg/ml of Beva by 48 hours; results are representative of three independent experiments, 
each one in triplicates; *p<0.05, **p<0.01, ***p≤0.001 Beva vs control. MCT1expression, but not MCT4 and CD147, increased in SW1088 
treated with 2mg/ml Beva during 48 hours by Western blot (B) and immunofluorescence (the cell nucleus were counterstained with DAPI 
and the pictures were taken at 400x in an Olympus fluorescence microscope) (C).
Oncotarget103662www.impactjournals.com/oncotarget
Figure 4: Pro-survival mechanism activated by Bevacizumab in GBM cells. Cells treatment with 2mg/ml of Beva during 
48 hours did not diminished the ROS production (A) and the ratio mitochondrial polarization/mitochondrial mass (B), the results are 
representative of three independent experiments. (C) Treatment of cells with 2 mg/ml of Beva increased the glycogen accumulation after 
48 hours; representative pictures of PAS staining were taken at 400x in an Olympus BX16 microscope; (D) Expression of phosphorylated 
Glycogen synthase kinase 3 (GSK3) also increased after Beva 2mg/ml treatment during 48 hours by western blot. (E) Western blot was also 
done for the autophagic markers LC3 I/II, p62 and IRF1 in U251 and SW1088 cells treated with 1 mg/ml and 2mg/ml of Beva during 48 
hours. Bafilomycin (BaF) was used to induce autophagy. The results showed that Beva has no impact on autophagy induction nor inhibition 
in the two cell lines.
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we verified an increase on glycogen synthase (GSK3) 
activation by increased expression of its phosphorylated 
form in both cell lines (Figure 4D). Concerning autophagy, 
we evaluated LC3I/II conversion and p62 expression 
by western blot and verified that Beva has no effect in 
autophagy induction or inhibition in both cell lines (Figure 
4E). Moreover, a recent in vitro experiment showed that 
Beva treatment increased IRF1 (Interferon-regulatory 
factor-1) expression in a dose and time dependent manner, 
which was coincident with Beva-mediated autophagy [42]. 
Thus, to confirm the lack of effect of Beva in autophagy 
induction we assessed also the levels of IRF1 by western 
blot (Figure 4E). Curiously, IRF1 levels seems to be 
unaltered in SW1088 cell line, and moderately increased 
in U251 upon Beva treatment, but is significantly 
decreased in both cell lines when autophagy is induced 
(by bafilomycin treatment) (Figure 4E).
In vivo tumor growth inhibition is pronounced 
when Bevacizumab is combined with glucose 
uptake blockers
Our findings suggested that in vitro Beva treatment 
induces metabolic alterations by increasing glucose 
consumption, lactate production and glycogen synthesis. 
Accordingly, we further aimed to study whether 
combination of Beva with a metabolic inhibitor can 
potentiate its effect and revert the metabolic status of the 
tumors. For that we performed the in vivo CAM assay, by 
using U251 cell line, and treated the tumors with Beva and 
2-DG (glucose analogue) alone, or both in combination. 
Overall, there is a slight decrease in the tumor mass in 
all the treatment conditions, mainly when Beva was 
combined with 2-DG (Figure 5A and 5B), although not 
reaching statistical significance. Concerning the effect 
of the agents on angiogenesis, we verified that all of 
them were extremely effective in reducing the tumors 
recruitment of blood vessels (Figure 5A and 5B).
The histological analysis of the CAM-formed 
tumors showed a central necrotic region in all experimental 
conditions (Figure 5C – HE 4x). Accordingly, we were 
able to confirm a higher number of death/necrotic cells in 
the tumors that were treated with 2-DG and with Beva+2-
DG (Figure 5C – HE 20x). By immunohistochemistry, 
we observed that the expression of hypoxic marker CAIX 
increased with either Beva or 2-DG treatment alone, and 
is weaker in the combination of Beva+2-DG (Figure 5C). 
We also observed an increase on GLUT1 expression after 
Beva treatment, as well as with 2-DG, with no changes 
in the combination group (Figure 5C). Regarding MCT 
expression, there was an increase in MCT1 expression, 
but not in MCT4, after Beva treatment alone. Combination 
of Beva + 2-DG decreased the MCT1 expression, 
however increased the MCT4 expression, probably due 
to the presence of 2-DG, condition in what we have also 
observed high levels of MCT4 (Figure 5C).
DISCUSSION
In the present study, aiming to unravel potential 
cellular mechanisms of resistance to anti-angiogenic 
drugs, we wondered whether Beva is able to induce 
glycolytic alterations in vitro and independently of oxygen 
deprivation. First, we observed that GBM cell lines 
express and secret VEGF, as previously described [43], 
and found that Beva is able to sequestrate all the VEGF 
secreted, decreasing in this way the cellular viability in a 
dose dependent manner. Importantly, we showed for the 
first time that Beva can be internalized by different cell 
lines. Ideally, antibodies suited to therapeutic applications 
must bind to and actively internalize their cognate 
target [44, 45]. Thus, we demonstrated here that Beva 
is functional in vitro and have a specific cytotoxic effect 
by totally abrogating the autocrine function of VEGF on 
tumor cells, corroborating the pertinence of its study in 
vitro.
By using two GBM cell lines with different 
metabolic behaviors [38, 39], we prove that Beva treatment 
promotes metabolic alterations on tumor cells, which are 
totally independent of hypoxia induction. Specifically, we 
found that Beva increases the glucose uptake and GLUT1 
expression as well as an increase in lactate production. 
These observations corroborate the in vivo mouse studies, 
where Beva leads to anaerobic metabolism increasing 
the levels of lactate, alanine, choline and some lipids, as 
well as to the increase of enzymes associated to glycolytic 
pathway, like GLUT3, HKII, LDHA and also enzymes 
associated to pentose phosphate pathway [29, 37].
In addition, beyond increased expression of hypoxic 
markers (HIF-1α and CAIX), that were already described 
in in vivo models [29, 30, 33, 37], we observed modulation 
of MCTs expression after Beva treatment, mainly the 
preferential location of MCT1 at the plasma membrane. 
Few studies reported modulation of MCT isoforms 
expression during anti-angiogenic therapy. A study of 
Curtarello M. et al. in ovary cancer, showed that Beva 
treatment increase MCT4 expression in most oxidative 
cells, without effect on glycolytic ones, and increased 
MCT1 expression, both in tumor and liver metastasis, 
only after Beva long term treatment [36]. In our study, the 
preferential increase of MCT1 upon Beva treatment could 
be explained by the knowledge that GBM cells prefer to 
use MCT1 for lactate efflux, in contrast to other tumors 
that prefer MCT4 [38, 39].
In addition to alterations on glucose metabolism, 
other metabolic alterations are known to occur in 
Beva treated tumors, which are concomitant with the 
upregulation of HIF-1α. In colorectal in vivo models, the 
metabolic assays revealed a significant impairment of 
mitochondrial function upon Beva treatment [26], and a 
significant increase in cellular senescence associated with 
upregulation of p16 in vitro [46]. In contrast, herein we 
found that Beva has no impact on mitochondrial function 
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Figure 5: In vivo effect of Bevacizumab in combination with glucose analogue 2-DG in U251 induced tumors. (A) In ovo 
pictures at 13th day of embryo development (4 days of tumor growth) and at 17th day (4 days of treatment, in ovo and ex ovo); representative 
pictures were taken at 20x in a Zeiss stereomicroscope. (B) Graphical representation of tumors perimeter (in relation to day 13 that was 
considered as 1 in each group) at the upper panel and of blood vessels (in relation to control without drugs, considered as 1) in the lower 
panel, showing a slight decrease on tumor size and significantly decrease in blood vessels on tumors treated with both Beva (2 mg/ml), 
2-DG (1 mM) alone and 2-DG plus Beva. The results are representative for a media of 8 eggs per group; ****p<0.001 treated group vs control 
for blood vessels counting. (C) H&E and IHC expression of hypoxia and metabolic markers after 4 days of treatment with Beva, 2-DG and 
2-DG+Beva. It is observed in the H&E a higher number of necrotic cells in the tumors that were treated with 2-DG and with Beva+2-DG. 
The IHC shows a decrease in CAIX expression in the combination group; GLUT1 increased in all groups; MCT1 expression increased after 
Beva treatment and decreased in combination group; MCT4 expression increased only in 2-DG conditions. The H&E pictures were taken 
with 4 and 20X objective, while and the ones from IHC were taken with 200X amplification in an Olympus microscope. The yellow line 
defines the necrotic area of U251 micro-tumors.
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or mass in U251 GBM cell line, but increase mitochondrial 
activity in the most oxidative one, the SW1088 cell line. 
Since our experiments were done in normoxia conditions, 
and that Beva increases the glucose consumption, is also 
expectable an increase on mitochondrial function in the 
more oxidative cell lines.
In GBM in vivo models it was described that 
hypoxia-mediated autophagy promotes tumor cell survival 
in patients that are resistant to Beva [41]. Importantly, it 
was recently shown that interferon-regulatory factor-1 
(IRF1) may regulate Beva-induced autophagy in GBM cell 
lines, and thus independently of hypoxia [42]. Herein, our 
in vitro study in normoxia conditions, showed that in fact 
Beva can somehow increase the expression levels of IRF1, 
but the association with an enhanced authophagy was not 
observed. Even we used the same antibody for IRF1, the 
cell lines used were different impairing comparisons with 
the previous work [42]. Importantly, our findings indicate 
that, at least at the cellular levels, alterations on glucose 
metabolism occur earlier and at lower doses than the 
impairment of mitochondria and autophagy induction.
A study of Pelletier J. and colleagues showed that 
glycogen synthesis is enhanced in GBM cells when 
exposed to hypoxia, resulting in a large increase in 
glycogen stores, induction of autophagy and senescence 
[40]. Knowing that, and since we found that Beva was 
able to increase the expression of HIF-1α independently of 
oxygen presence, and that the rates of glucose uptake were 
higher than the ones of lactate export, we hypothesized 
whether the glucose is being used for glycogen storage 
in GBM treated cell lines. In fact, we demonstrated that 
Beva treatment increase glycogen accumulation and 
activity of glycogen synthase kinase in GBM cell lines, 
probably as a survival mechanism imposed by pseudo-
hypoxia generation. The glycogen storage could be used as 
intermediate source for biosynthetic pathways and prevent 
cell death [40].
The discovery of alterations on glycolytic 
metabolism as a putative mechanism of resistance to 
anti-angiogenic therapy, offers the opportunity for new 
and effective combinatory therapeutic approaches. It is 
known that suppressing HIF-1α, with low-dose topotecan, 
potentiates the effects of the antiangiogenic drugs in 
mouse models of neuroblastoma and GBM [47, 48]. In 
colorectal cancer xenograft models, treatment of Beva-
resistant cells with the glycolysis inhibitor 3-BP resulted 
in smaller tumor volume and longer survival [26], while 
Beva and DCA together dramatically blocked tumor 
growth compared to either drug alone [49], suggesting that 
glycolysis blockage may also potentiate the therapeutic 
effect of anti-angiogenic treatment [26, 49]. Inhibition of 
CAIX expression, as well as its activity in GBM, leads to 
a synergistic decrease on xenograft tumor growth when 
combined with Beva [31].
Our results showed that Beva drives an earlier increase 
on glucose uptake and glycogen storage, before the appearance 
of other metabolic alterations, therefore, we use 2-DG, an 
analogue of glucose uptake, as an alternative strategy to 
enhance the Beva effects in vivo. By inducing U251 micro-
tumors in in vivo CAM assay, we verified that the combined 
treatment leads to a decrease in tumor growth and angiogenesis, 
but has no additional effects when compared to Beva alone. 
Histologically, we observed that the tumors treated with both 
Beva and 2-DG have decreased expression of CAIX, MCT1 
and increased MCT4, suggesting somehow a restoring on 
the glycolytic alterations driven by Beva treatment alone. 
However, further in vivo studies, mainly in mouse models, 
are warranted to validate and explore that findings.
In conclusion, that was the first in vitro study seeking 
to understand the effects of Beva on cellular metabolism, 
independently of the tumor microenvironment. The 
findings re-enforces our hypothesis that Beva can be 
used in vitro, being functional and having biological 
and cytotoxic activity. Importantly, we found that Beva 
is able to alter the cellular metabolism of cancer cells 
by abrogating VEGF autocrine function. Thus, the 
exploitation of anti-angiogenic drugs effect at the cellular 
level can open the opportunity to discover new therapeutic 
strategies to overcome Beva resistance in vivo.
MATERIALS AND METHODS
Cell culture and cell lines
Seven immortalized GBM cell lines were used: 
SW1088, SW1783, U-87 MG and A172 were obtained 
from ATCC (American Type Culture Collection), SNB-
19 and GAMG were obtained from DSMZ (German 
Collection of Microorganisms and Cell Cultures) and 
U251 was kindly provided by Professor Joseph Costello. 
Human Brain Microvascular Endothelial Cells (HBMEC) 
cell line was kindly provided by Professor Kwang Sik 
Kim, John Hopkins School of Medicine, Baltimore, USA. 
All the cell lines were maintained in DMEM supplemented 
with 10% FBS, at 37°C and 5% CO2.
Authentication of cell lines was performed in our lab 
by short tandem repeat (STR) DNA typing according to 
the International Reference Standard for Authentication of 
Human Cell Lines using a panel of 8 (D5S818, D13S317, 
D7S820, D16S539, vWA, TH01, TPOX and CSF1P0) 
STR loci plus gender determination (AMEL) [50]. The 
genotyping confirmed the identity of all cell lines.
Drugs
Bevacizumab (Avastin®; Genentech) was kindly 
provided by the Pharmacy Department from Hospital 
de S. João, Porto. The 2-deoxy-D-glucose (2-DG) was 
purchased from Sigma-Aldrich, and reconstituted at stock 
concentration of 1M in water. Bafilomycin A1, (BaF) was 
purchased from Santa Cruz Biotechnology (sc-201550) at 
a stock concentration of 1 mM in DMSO.
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Antibodies
For immunofluorescence (IF) and Western blot 
(WB) assays, we used the following antibodies and 
dilutions: VEGF [(1:100 dilution (IF), 1:500 dilution 
(WB), RM 9128-S0; NeoMarkers)]; Bevacizumab 
(1:100 dilution (IF), Genentech); MCT1 [(1:200 dilution, 
AB3538P; Chemicon International (IF)), (1:500 dilution; 
H-1, sc-365501; Santa Cruz Biotechnology (WB))]; 
MCT4 (1:500 dilution; H-90; sc-50329; Santa Cruz 
Biotechnology); CD147 (1:500 dilution, 1.BB.218, sc-
71038; Santa Cruz Biotechnology); HKII (1:4000 dilution, 
ab104836, Abcam); GLUT-1 (1:500 dilution, ab15309, 
Abcam); HIF-1α [(1:100 dilution (IF); 1:500 dilution 
(WB), 610958, BD Biosciences), LDHA (1:1000 dilution, 
E9, sc-137243, Santa Cruz Biotechnology), CAIX 
(1:2000 dilution, ab15086, Abcam); LC3A/B (1:1000 
dilution, 4108, Cell Signaling Technology); p62 (1:1000 
dilution, sc-28359, Santa Cruz Biotechnology); IRF1 
(1:1000 dilution, sc-135952, Santa Cruz Biotechnology); 
α-Tubulin (1:5000 dilution, B-5-1-2, sc-2394, Santa Cruz 
Biotechnology) and GAPDH (1:1000 dilution, sc-69778, 
Santa Cruz Biotechnology).
Cell viability assay
Glioma cells were plated into 96-well plates in 
triplicates at a density of 20x103 cells/well and allowed 
to adhere overnight in complete DMEM medium. Then, 
cells were treated with increased concentrations of Beva 
in DMEM 0.5% FBS during 72 hours. The viable cells 
were quantified using the Cell Titer96 Aqueous cell 
proliferation assay (Promega). The results were expressed 
as the mean percentage ± SD of viable cells relatively 
to control condition (considered as 100% viability). The 
IC50 concentration was calculated by nonlinear regression 
analysis using the GraphPad Prism software, as previously 
described [51]. The assay was performed in triplicate at 
least three times.
Immunofluorescence
For indirect immunoﬂuorescence the cells were 
seeded on cover slips at density of 20x103 cells/well, 
overnight. When necessary, the cells were incubated 
during 24-48h with 2mg/ml Beva in DMEM 0.5% FBS. 
Then, cells were fixed and permeabilized in methanol 
during 20min. After blocking with 5% bovine serum 
albumin (BSA) for 30min, cells were incubated overnight 
at room temperature with the primary antibodies. Then, 
1h of incubation with the secondary antibody anti-Human 
IgG-Alexa Fluor 488 (1:500 dilution, A11013, Invitrogen) 
in 5% BSA was performed for Beva; anti-rabbit-Alexa 
Fluor 568 (1:500 dilution, A11011, Invitrogen) in 5% 
BSA was performed for VEGF; anti-rabbit-Alexa Fluor 
488 (1:500 dilution, A11008, Invitrogen) in 5% BSA 
was performed for MCT4, MCT1 and GLUT-1 and 
anti-mouse-Alexa Fluor 594 antibody (1:250 dilution, 
A11032, Invitrogen) for CD147, HKII, LDHA and CAXI. 
Additionally, to see the internalization of Beva, the cells 
exposed to Beva during 24h, we directly incubated with an 
anti-Human IgG-Alexa Fluor 488 (1:500 dilution, A11013, 
Invitrogen) after fixation and blocking.
Finally, after washing in PBS, cells were mounted 
in Vectashield Mounting Media with 4′,6-diamidino-2-
phenylindole (DAPI) (Vector Laboratories) and images 
were obtained with a fluorescence microscope (Olympus 
IX81), using the Cell P software.
ELISA
To quantify the levels of VEGF in the culture 
medium before and after Beva treatment we used 
the Human VEGF ELISA Kit (KHG011, Novex), as 
recommended by the manufacture. The cells were cultured 
at a density of 10x103 and 20 x103 cells/well in a 12-well 
plate, and after 24 hours’ treatment with Beva (2mg/ml) 
the culture medium was collected for ELISA analysis. The 
results were expressed as mean pg/ml ± SD.
Western blotting
The cells were seeded in 6-well plate at density of 
2.5x105 cells/well and allowed to adhere overnight. After, 
48hours of 2mg/ml Beva treatment, cells were collected 
for protein extraction. For autophagy assessment, the cells 
were plated in six-well plates at a density of 1x106 cells/
well, and allowed to adhere for at least 24 h. Then the 
growth medium was replaced with fresh growth medium 
for the control cells or with 20 nM bafilomycin A1 (BaF 
– autophagy inducer) with and without 2mg/ml of Beva, 
during 48 hours. Western blot was performed as described 
previously [38, 51]. Incubation with primary antibodies 
was performed overnight at 4ºC. The bound antibodies 
were visualized by chemiluminescence (Supersignal West 
Femto kit; Pierce).
Extracellular lactate and glucose measurements
Cells were plated in 48 well plates at a density of 
3x104 cells per well and allowed to adhere overnight. 
Lactate and glucose contents were analyzed in cell culture 
medium after 48h of 2mg/ml Beva treatment, using 
commercial kits (Spinreact), as described [38, 39]. For 
these time points, the total protein (expressed as total 
biomass) was assessed using the sulforhodamine B assay 
(SRB, TOX-6, Sigma-Aldrich). Results are expressed as 
total μg/ total biomass.
ROS production and mitochondrial activity
Cells were plated in 6 well plate at a density of 2.5x105 
cell/well and treated with 2mg/ml Beva during 48 hours. 
Then, cells were incubated with the molecular probes during 
Oncotarget103667www.impactjournals.com/oncotarget
2h at 37º, in dark. After, molecular probe incubation, the 
cells were washed with PBS and collected to flow cytometry 
analysis (LSRII, BD Biosciences). For measurement 
of ROS content, cells were incubated with 200nM of 
Dihydroethidium (DHE, Molecular Probes). Mitochondrial 
polarization was assessed by 200nM Mitotracker Red and 
mitochondrial mass by 200nM Mitotracker Green (Molecular 
probes). The mitochondrial activity was represented as the 
ratio mitochondria polarization: mitochondria mass.
Glycogen accumulation
Glycogen accumulation in cells was observed through 
the Periodic and Schiff (PAS) staining. The cells were plated 
at density of 5x104 cell/well and allowed to adhere overnight. 
Then 2mg/ml Beva treatment was performed in DMEM 
0.5% FBS during 48hours. After that cells were fixed in 
4% paraformaldehyde (PFA) for 15minutes, followed the 
incubation with periodic acid for 5minutes and then Schiff 
reagent for 10 minutes. Periodic acid oxidizes the vicinal 
diols in glycogen and form a pair of aldehydes with reacts 
with Schiff reagent and give a purple-magenta color. In the 
end, hematoxylin was used to do counterstaining.
Chicken chorioallantoic membrane (CAM) assay
CAM assay was performed as described previously 
[52]. At 9 day of development, 2x106 cells were injected 
with Matrigel on CAM, allowing the tumor formation 
during 4 days. On 13 day, tumors were photographed 
and treated with the respective conditions: control group, 
2mg/ml Beva group, 1mM 2-Deoxy-D-glucose (2DG) 
group or 1mM 2-DG + 2mg/ml Beva. After 96 hours, 
CAMs were dissected, fixed in 4% paraformaldehyde 
and photographed to vessel counting and perimeter 
measurement. Vessels was counted using the ImageJ 
14.1 version software. The results of the perimeter at the 
17 day were expressed in fold change in relation to the 
mean perimeter of the tumors at the day 13 (considered 
as 1). The results of the number of blood vessels at day 
17 were expressed in fold change in relation to the control 
(considered as 1).
Statistical analysis
For the in vitro and in vivo studies, the GraphPad 
prism 5 software was used to statistical analysis, with the 
Student’s t test or the One-Way ANOVA test, considering 
significant values p<0.05.
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